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Abstract
Introduction:  -Lactams are among the most widely prescribed antibiotics in human medicine. However,
because of their massive and usually inappropriate use, resistance to these drugs has increased markedly,
especially due to extended-spectrum -lactamase (ESBL) production.
Objectives:  The aims of this study were to determine the prevalence of urinary Escherichia  coli  strains
isolated from urine samples taken from patients diagnosed with urinary tract infections (UTIs), to evaluate
their current antimicrobial susceptibility pattern and to look for blaSHV, blaTEM and blaCTX-M genes in
these multi-drug resistant isolates.
Subject  and  methods:  A retrospective survey was made over 3 years from 2010 to 2012. It included all
uropathogenic E.  coli  strains isolated from urine samples taken from consulting and hospitalized patients
in the Avicenne Teaching Hospital in Marrakech, Morocco.
Results:  E.  coli  was the etiologic agent in 63% of reported UTIs due to Enterobacteriacae. In all, the
prevalence of ESBL-producing E.  coli  reached 6% of all urinary Enterobacteriaceae  isolates in 2012.
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The bacterial resistance rates of ESBL-producing E.  coli  isolates were as follows: amoxicillin/clavulanic
acid (100%), trimethoprim/sulfamethoxazole (76%), gentamicin (66%), ciprofloxacin (82%) and amikacin
(56%). None of these strains was resistant to carbapenems. The ESBL production patterns observed included
single production of CTX-M (70%), SHV (12%) and TEM (0%). Some ESBL-producing E.  coli  isolates
produced combinations of 2 ESBLs belonging to different groups: CTX-M+SHV (12%) and CTX-M+TEM
(6%).
Conclusion:  The results of this work report, for the first time in the Marrakech region, the ESBL production
pattern with CTX-M being most common among the ESBL-producing urinary E.  coli. Moreover, a major
finding is the production of multiple ESBL types by some urinary E.  coli  isolates.
© 2015 Pan African Urological Surgeons’ Association. Production and hosting by Elsevier B.V. All rights reserved.
Introduction
Escherichia  coli, a member of the Enterobacteriaceae  family, has
been reported to be one of the most predominant organisms caus-
ing urinary tract infections (UTIs) which are very common reasons
for consultation and antibiotic prescription in current practice [1,2].
Massive and usually inappropriate use of antibiotics for treatment
of UTIs generates a selective pressure that is followed by the
rapid emergence and spread of multi-drug resistant bacterial strains.
Nowadays, resistance of uropathogenic E.  coli  to many antibiotic
classes is a very common finding in human medicine and is usually
associated with increased medical costs, prolonged hospital stays
and frequent therapeutic failure [3].
The production of extended-spectrum -lactamases (ESBL) by
urinary E.  coli  strains is a major public health concern in both hos-
pital and community settings [2]. These ESBL-producing strains
represent a significant therapeutic challenge as they are resistant
to all currently available -lactam antibiotics but cephamycins
(e.g., cefoxitin and cefotetan) and carbapenems (e.g. imipenem and
ertapenem) [4].
Resistance to expanded-spectrum cephalosporins by ESBL produc-
tion is mainly due to members of the TEM and SHV families of
enzymes. The distribution of ESBLs has evolved to a predominance
of CTX-M enzymes, mainly with E.  coli  as one of the major carri-
ers of ESBL-encoding genes. Nowadays, the class-A ESBLs, TEM,
SHV and CTX-M types, are the most widespread and clinically
relevant [5].
During the last three decades, ESBLs among urinary E.  coli  have
been reported worldwide, and their occurrence has increased in
both outpatients and inpatients diagnosed with UTIs. As for most
developing countries in Africa, ESBL-producing bacteria have been
examined in only a few studies. Limited data from prior studies con-
ducted in Morocco suggest that ESBLs are common in Moroccan
hospitals [6,7], with blaCTX-M, blaSHV and blaTEM genes rep-
resenting the main reported ESBL families [8,9]. ESBL-producing
E.  coli  isolates from the Marrakech region have not been character-
ized previously. Therefore, the aims of this present study were to
determine the prevalence of ESBL-producing E.  coli  of both com-
munity and nosocomial origin isolated from urine samples taken
from patients diagnosed with UTIs, to detect their drug resistance
pattern to commonly used antibiotics in medical practice and to
detect blaSHV, blaTEM and blaCTX-M genes in these multi-drug
resistant isolates.
Figure  1  The double-disk synergy test performed on a 100 mm
Mueller-Hinton agar plate: a clinical E.  coli  isolate, positive result.
Subject  and  methods
All clinical non-duplicate E.  coli  isolates isolated from urinary
samples at the microbiology laboratory of Avicenne University Hos-
pital (Marrakech, Morocco) over a 3-year period (2010–2012) were
included in this study. This university hospital serves wide urban
and rural geographic areas in the Marrakech region.
Urinary E.  coli  isolates were identified to the species level, tested
for antimicrobial susceptibility and screened for ESBL production
using custom MicroScan Walkaway dehydrated broth microdilu-
tion panels (MicroScan®, Sacramento, CA, USA) according to the
Antibiogram Committee of the French Society of Microbiology
(CA-SFM) guidelines [10].
Phenotypic ESBL production was confirmed by the double-disk
synergy test “DDST” (Fig. 1). This phenotypic ESBL screening
test is based on the demonstration of a synergy image between
Amoxicillin/clavulanic acid (20/10 mg) and cefotaxime (30 mg),
ceftazidime (30 mg) and aztreonam (30 mg) according to the guide-
lines of the CA-SFM [10].
Twenty-five percent (17/67) of the ESBL-producing E.  coli  isolates
were randomly chosen to undergo ESBL molecular characterization
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Table  1  Antimicrobial susceptibility profiles and bla genes detected by PCR in seventeen ESBL-producing E.  coli.
Isolate no. DDST Antimicrobial susceptibility testing ESBL genes
Amx Amc cf Tic Fox Ctx Caz Fep Imp Fos Gm Tm Ak Sxt Cip
E. coli 1 + R R R R S R R R S S R R S R R CTX-M1
E. coli 2 + R R R R S R R R S S R R R S R CTX-M1
E. coli 3 + R R R R S R R R S S R R R R R CTX-M1
E. coli 4 + R R R R S R R R S R R R S R R CTX-M1
E. coli 5 + R R R R S R R R S S R R S R R CTX-M1 no gr 1
E. coli 6 + R R R R S R R R S S R R R S R CTX-M1
E. coli 8 + R R R R S R R R S S R R R R R CTX-M1 no gr 1
E. coli 9 + R R R R S R R R S S R R R R R CTX-M1
E. coli 10 + R R R R S R R R S S R R R R R CTX-M1
E. coli 11 + R R R R S R R R S S R R R S S CTX-M1
E. coli 12 + R R R R S R R R S S S S S R R CTX-M1
E. coli 13 + R R R R S R R R S S S S S S R SHV
E. coli 14 + R R R R S R R R S S R R S S R SHV
E. coli 15 + R R R R S R R R S S R R R S S CTX-M1/SHV
E. coli 16 + R R R R S R R R S S R R R R R CTX-M1/SHV
E. coli 17 + R R R R S R R R S S R R R R R CTX-M1/TEM
E. coli 18 + R R R R S R R R S S R R R R R CTX-M1
Amx: amoxicillin, Amc: amoxicillin/clavulanate; Cf: céfalotine; Tic: ticarcillin; Fox: cefoxitin; Ctx: cefotaxime; Caz: ceftazidime; Fep: cefepime; Fos:
fosfomycine; Imp: imipenem; Gm: gentamycine; Tm: tobramycine; Sxt: sulfamethoxazole; Cip: ciprofloxacine, Nal: nalidixic acid; Ak: amikacine; +:
positive; −: negative; R: resistant; S: sensible.
Table  2  Nucleotide sequences of polymerase chain reaction
(PCR) primers used in this study.
Gene Primer sequence (5′–3′)
CTX-M
group1
CTX-M (F): GGTTAAAAAATCACTGCGTC
CTX-M (R): TTGGTGACGATTTTAGCCGC
SHV
SHV (F): CGCCGGGTTATTCTTATTTGTCGC
SHV (R): CGCCGGGTTATTCTTATTTGTCGC
TEM
TEM (F): ATAAAATTCTTGAAGACGAAA
TEM (R): GACAGTTACCAATGCTTAATCA
(Table 1). The conserved core regions of the blaCTX-M, blaSHV
and blaTEM genes, which represent the most commonly reported
ESBL families in Morocco, were amplified by PCR to identify the
families of ESBL enzymes produced by urinary E.  coli  isolates in
the Marrakech region. PCR amplification of bla genes was carried
out using the primers listed in Table 2.
Results
During the three-year study period (2010–2012), a total of 1472
Enterobacteriaceae  isolates was recovered from culture specimens
of patients diagnosed with UTIs. Of these, the most frequent Entero-
bacteriaceae  strains isolated from urinary samples were E.  coli
(63%, n  = 924). E.  coli  strains accounted for 86% of the community-
acquired UTIs.
The bacterial resistance patterns of non-ESBL producing E.  coli  iso-
lates and ESBL-producing E.  coli  isolates are presented in Table 3.
During the study period, the percentage of E.  coli  strains resistant
to third-generation cephalosporins by ESBL production increased
progressively from 3% in 2010 to 4% in 2011 and 6% in 2012 of
all isolated urinary Enterobacteriaceae  (overall 4.5%; 67/1472). All
E.  coli  isolates were susceptible to carbapenems (e.g. imipenem and
ertapenem).
Table  3  Antimicrobial resistance rates between non-ESBL and
ESBL producing urinary E.  coli  strains  recovered in the Marrakech
region between January 2010 and December 2012.
Tested antibiotic ESBL producing
E. coli strains
(%R) (n = 67)
Non-ESBL
producing E. coli
strains (%R)
(n = 857)
Amx 100 65
Aug 100 43
T/S 76 55
Gm 66 14
Cp 82 22
Ak 56 8
Fd 13 11
Fos 9 7
Etp 0 0
Imp 0 0
T/S: trimethoprim/sulfamethoxazole; Aug: amoxicillin/clavulanate; Cp:
ciprofloxacin; Gm: gentamicin; Fd: nitrofurantoin; Ak: amikacin; Fos:
fosfomycin; Imp: imipenem; Etp: ertapenem.
The distribution of ESBL-producing genes is detailed in Fig. 2. The
ESBL production patterns observed included single production of
CTX-M (70%), SHV (12%), TEM (0%) and some combinations of
2 ESBLs belonging to different groups: CTX-M1+TEM (6%) and
CTX-M+SHV (12%).
Discussion
This study included all E.  coli  isolates responsible for community
and nosocomial acquired UTIs recovered at the Avicenne Teaching
Hospital of Marrakech, Morocco between 2010 and 2012. Although
UTIs caused by ESBL-producing E.  coli  are a cause of concern due
to clinical failure of empirical treatment protocols in the Marrakech
region [6], there were no available data regarding the prevalence
and characteristics of ESBL-producing E.  coli  from the Marrakech
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Figure  2  Distribution of genes encoding extended spectrum -
lactamase (ESBL) among 100 clinical isolates of ESBL producing
E. coli.
region before this study. We found that E.  coli  was the etiologic
agent in 63% of UTIs due to Enterobacteriaceae. This high isolation
frequency of urinary E.  coli  is clearly justified by the preponderance
of E.  coli  in the general profile of bacteria responsible for UTIs [11].
Characteristic of antimicrobial resistance are the differences
between regions, hospitals and even departments. E.  coli  strains
are susceptible to commonly used antimicrobial agents in treatment
of UTIs. However, antibiotic resistance of uropathogenic E.  coli  in
UTIs is increasing worldwide. Our study showed that non-ESBL
producing E.  coli  isolates have alarming bacterial resistance rates
to most prescribed antimicrobial agents tested, such as amoxicillin
(65%), amoxicillin-clavulanic acid (AMC) (43%), T/S (55%) and
ciprofloxacin (22%). The high antimicrobial resistance to these
antimicrobial agents widely prescribed in Morocco [12] justifies that
they are currently no longer recommended for empirical treatment
of UTIs [13]. Many factors have contributed to such high bacterial
resistance rates. They include massive use and misuse of antibiotics
both in hospitals by health professionals and in the community by
self-prescription as well as inadequate antimicrobial surveillance
programs.
Over the past decade, the occurrence of ESBLs among Enterobacte-
riaceae  isolated from urine samples of both in- and outpatients has
been assessed in several studies [6,14–16]. UTIs caused by ESBL-
producing Enterobacteriaceae  have been reported worldwide, and
our study disclosed a high prevalence of ESBL-producing E.  coli.
Antimicrobial resistance testing showed a very important vari-
ety when comparing ESBL and non-ESBL producing strains of
E.  coli  (Table 3). The mean percentages of resistance to com-
monly used antibiotics measured in the ESBL-producing E.  coli
were remarkably higher than the antimicrobial resistance percent-
ages displayed by non-ESBL producing E.  coli  isolates. Indeed, all
ESBL-producing E.  coli  showed higher resistance rates to amino-
glycosides, T/S and fluoroquinolones. This finding suggests that
ESBL-encoding genes and genes encoding other classes of antibi-
otics were on the same plasmids and therefore spread together
[17,18]. Fluoroquinolones and T/S are often used to treat UTIs
caused by Enterobacteriaceae  in various clinical settings. Our
results showed that 82% and 76% of the ESBL-producing isolates
were resistant to ciprofloxacine and T/S, respectively. The associ-
ation of ESBL production and resistance to fluoroquinolones and
T/S has been reported worldwide, and the widespread use of fluo-
roquinolones has been identified as a risk factor for the emergence
of fluoroquinolone-resistant ESBL-producing strains [19–21].
The clinical relevance of ESBLs has been well documented by
numerous published reports describing clinical failure with antimi-
crobial agents supposed to be effective [22]. Thus, the choice of
antimicrobial agents effective against ESBL-producing organisms
is currently very limited to a few classes of antibiotics, such as car-
bapenems, that are often the recommended treatment of UTIs caused
by ESBL-producing E.  coli.  However, carbapenemase-producing
Enterobacteriaceae  are increasingly being reported and are becom-
ing a major clinical and public health concern in many countries
including Morocco [8]. The antimicrobial susceptibility results
show that imipenem and ertapenem remain the most effective drugs
against urinary E.  coli  isolates. Nevertheless, there remains a need
for continuous surveillance and judicious use of this class of antibi-
otics to prevent the emergence of carbapenem-resistant E.  coli
isolates in our region.
Molecular detection and identification of -lactamases would be
essential for a reliable epidemiological investigation of antimicro-
bial resistance. Until now, ESBL genes have been studied in different
parts of the world but not in the Marrakech region. This is the first
systematic study that reports the diversity of ESBL genes among
ESBL-producing urinary E.  coli  isolated in this region. Three types
of ESBL were detected in our study: CTX-M, SHV and TEM.
Clearly, CTX-M ESBLs are the most prevalent among single ESBL
types produced by E.  coli  in our study, accounting for 70% of the
ESBLs compared with SHV (12%) and TEM (0%). This is a dra-
matic turnaround from the situation in the 1990s when TEM and
SHV ESBLs were dominant and CTX-M types were rarely rec-
ognized. The distribution of ESBL-producing genes in our series,
with a large predominance of CTX-M, is similar to those reported
in several countries including Argentina, the UK, Spain, France and
India [5,22–25], among others countries where CTX-M-producing
Enterobacteriaceae  have been described to be endemic.
Multiple ESBL-producing E.  coli  appear to occur worldwide.
Among the 17 tested strains of ESBL-producing E.  coli, 3 strains
were found to harbor bla genes for two ESBLs of different families
(Table 1). The combination of blaCTX-M with blaSHV predomi-
nated in isolates producing two ESBLs (dual ESBLs). This finding
confirms the accumulation of multiple types of bla genes in E.  coli
isolated in the Marrakech region.
The class-A ESBLs, TEM, SHV and CTX types, are the most
widespread and clinically relevant worldwide [26]. In Morocco,
ESBL-producing Enterobacteriaceae  have been isolated from sam-
ples collected in different hospitals [6,7], and the ESBL-positive
strains frequently expressed blaCTX-M among other ESBLs such
as blaTEM, blaSHV, blaDHA and blaOXA types [27]. CTX-M
ESBLs are the most commonly described ESBL types in Tunisia
[28] and Algeria [29,30]. This also illustrates the large spread of
ESBL-producing E.  coli  in the North African countries.
Originally, ESBLs were most commonly reported to be a
hospital-based problem. However, there are now numerous reports
that ESBLs are becoming common among community-acquired
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pathogens, especially among E.  coli. In particular, the CTX-M fam-
ily of ESBLs has been reported to be the most prevalent among
the ESBL-produced enzymes in community-onset UTIs worldwide
[31].
Conclusion
This is the first systematic study of ESBL types produced by urinary
E.  coli  in the Marrakech region. The results of this survey demon-
strate a high prevalence of ESBL-producing E.  coli  with important
antimicrobial resistance rates to commonly used antibiotics. We also
report the diversity of ESBL genes harbored by ESBL-producing
E.  coli, with CTX-M ESBLs being most common. The important
dissemination of ESBL-producing E.  coli  has lead to a decrease in
therapeutic options and to an increase in hospital costs. Therefore,
updates of trends for regional epidemiological data on antimicrobial
resistance are crucial in order to promote appropriate antimicrobial
therapy as well as an effective infection control and clinical care
management.
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